Please login to the form below

Not currently logged in
Email:
Password:

neurogenics

This page shows the latest neurogenics news and features for those working in and with pharma, biotech and healthcare.

Merck buys cough drug developer Afferent for $1.25bn

Merck buys cough drug developer Afferent for $1.25bn

Merck buys cough drug developer Afferent for $1.25bn. Gains access to pipeline with potential for development in ‘ neurogenic’ indications. ... These receptors seem to become more common after nerve injury or inflammation, and drugs that block them

Latest news

  • Lundbeck agrees $658m deal to buy Chelsea Therapeutics Lundbeck agrees $658m deal to buy Chelsea Therapeutics

    Chelsea's marketed product - Northera (droxidopa) - was given a green light by the US FDA in February as the first drug specifically approved to treat symptomatic neurogenic orthostatic hypotension (NOH), a

  • FDA approves Chelsea's rare blood pressure drug FDA approves Chelsea's rare blood pressure drug

    The Food and Drug Administration (FDA) backed Northera capsules (droxidopa) to treat neurogenic orthostatic hypotension (NOH), a chronic drop in blood pressure that is found in patients with Parkinson's disease, ... People with neurogenic orthostatic

  • FDA panel backs Chelsea's Northera for rare disease FDA panel backs Chelsea's Northera for rare disease

    The regulator's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 16 to 1 in favour of the approval of Northera (droxidopa) to treat symptomatic neurogenic orthostatic hypotension (nOH) in patients ... with an underlying neurogenic disorder,

  • Scott Whitcup joins Questcor’s board of directors

    The company said his experience in commericialising Botox as a treatment for chronic migraine, upper limb spasticity and neurogenic urologic conditions would be beneficial in Questcor's efforts to expand the

  • Positive opinion for Allergan's NDO treatment

    Positive opinion for Allergan's NDO treatment. A positive opinion is given from the Irish Medicines Board for BOTOX treatment for neurogenic detrusor overactivity (NDO). ... NDO results from neurogenic bladder, due to stable sub-cervical spinal cord

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    in development for the treatment of neurogenic conditions, such as chronic cough.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    825. Chelsea Therapeutics/ Lundbeck. Company acquisition. Includes Northera (droxidopa) for neurogenic orthostatic hypotension (approved).

  • Pharma deals during May 2014 Pharma deals during May 2014

    Chelsea has the recently FDA-approved droxidopa, the first and only symptomatic treatment for neurogenic orthostatic hypotension ready for launch later this year.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics